Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open‐label phase 3 study

A phase 3, multicenter, open‐label, 52‐week study investigated the efficacy and safety of adalimumab 80 mg at week 0 followed by adalimumab 40 mg every other week (option to escalate to 80 mg when necessary) in Japanese patients with generalized pustular psoriasis (GPP). Adults (aged 15–75 years) wi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of dermatology 2018-12, Vol.45 (12), p.1371-1380
Hauptverfasser:	Morita, Akimichi, Yamazaki, Fumikazu, Matsuyama, Takashi, Takahashi, Kenzo, Arai, Satoru, Asahina, Akihiko, Imafuku, Shinichi, Nakagawa, Hidemi, Hasegawa, Yuichi, Williams, David, Matsuda, Naoto, Kitamura, Susumu
Format:	Artikel
Sprache:	eng
Schlagworte:	adalimumab Adalimumab - therapeutic use Adult Aged Anti-Inflammatory Agents - therapeutic use Edema Erythema Female generalized pustular psoriasis Humans Hypoalbuminemia - chemically induced Hypoalbuminemia - epidemiology Immunotherapy Japan - epidemiology Japanese patient Male Middle Aged Monoclonal antibodies Nasopharyngitis - chemically induced Nasopharyngitis - epidemiology Original Patients prospective clinical trial Pruritus Pruritus - chemically induced Pruritus - epidemiology Psoriasis Psoriasis - diagnosis Psoriasis - drug therapy Psoriasis - pathology Remission Rhinopharyngitis Severity of Illness Index Skin - drug effects Skin - pathology TNF inhibitors Treatment Outcome tumor necrosis factor‐α inhibitor Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!